Obesity (Silver Spring, Md.)Feb 23, 2023

Estimated lowest national and minimum prices of anti-obesity drugs to improve treatment access and affordability

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗OA ↗

Updated Mar 28, 2026

Abstract

Semaglutide prices for a 30-day course vary from $804 in the United States to $95 in Turkey, while the estimated minimum price is $40.

National prices of antiobesity medications are significantly higher than the calculated estimated minimum prices (EMPs).
Liraglutide prices range from $1418 in the United States to $252 in Norway, with an EMP of $50.
Some oral antiobesity treatments may be produced at very low costs, such as orlistat at $7 per course and phentermine/topiramate at $5.
The naltrexone-bupropion combination is estimated to cost $54, indicating higher production expenses compared to other treatments.
The wide variation in medication prices across countries could limit access for individuals needing these treatments.

Simplified

OBJECTIVE: Novel antiobesity treatments are highly effective in recent clinical trials. Access to these medications is needed to supplement lifestyle and surgical interventions for millions living with obesity worldwide, but high prices are limiting. This study aimed to review current treatment costs and calculate potential estimated minimum prices (EMPs).

METHODS: The authors searched national drug price databases across various countries for orlistat, naltrexone-bupropion, topiramate-phentermine, liraglutide, semaglutide, and tirzepatide. EMPs for antiobesity medications were calculated using established methodology, using active pharmaceutical ingredients (API) from the Panjiva database. EMPs were calculated per 30-day course and include costs of active pharmaceutical ingredients, excipients, formulation, taxation, and 10% profit margin.

RESULTS: National prices of antiobesity medications were significantly higher than calculated EMPs. Semaglutide 30-day course prices ranged from $804 (United States) to $95 (Turkey) while the EMP was $40. Liraglutide prices ranged from $1418 (United States) to $252 (Norway) while the EMP was $50. Some oral treatments could be generically manufactured at very low costs per course ($7 for orlistat; $5 for phentermine/topiramate combination tablets), while naltrexone/bupropion was more expensive ($54).

CONCLUSIONS: This study shows that certain weight loss treatments can be manufactured and sold profitably at low costs, but prices currently range widely between countries, limiting access for those in need.

Full Text

Full text is available at the source.

View Full Text ↗

Estimated lowest national and minimum prices of anti-obesity drugs to improve treatment access and affordability

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the glp-1 therapies brief

Abstract

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the glp-1 therapies brief